Table 5:
Relative Risk of Response for Pharmacogenomic-Guided Medication Selection Compared With Treatment as Usual Based on Alternative Depression Scales
| Measure | Author, Year (Primary Study) | % Response (n/N) | RR (95% CI) | P Value | |
|---|---|---|---|---|---|
| PGx | TAU | ||||
| GeneSight | |||||
| QIDS-C16 | Greden et al, 201957 | 34.1 (212a/621) | 31.4 (213a/678) | 1.09 (0.93–1.27) | .29 |
| Hall-Flavin et al, 201355 | 44.4 (32/72) | 23.7 (22/93) | 1.88 (1.20–2.94) | .005 | |
| 9-Item Patient Health Questionnaire | Greden et al, 201957 | 39.7 (247a/621) | 31.6 (214a/678) | 1.26 (1.09–1.46) | .01 |
| Hall-Flavin et al, 201355 | 50.7 (36/72) | 31.2 (29/93) | 1.60 (1.10–2.35) | .01 | |
| HAM-D6 | Dunlop et al, 201966 (Greden et al, 201957) | 29.6 (184a/621) | 22.5 (152a/677) | 1.32 (1.10–1.59)a | .004 |
| Neuropharmagen | |||||
| PGI-I (score ≤ 2) | Perez et al, 201762 | 12 wk: 47.79 (NR) 8 wk 40.56 (NR) 4 wk: 28.47 (NR) |
12 wk: 36.11 (NR) 8 wk: 37.41 (NR) 4 wk: 31.97 (NR) |
OR 1.62 (1.0–2.61) NR NR |
.047 NS NS |
| PGI-I (sustained responseb) | 38.5 (NR) | 34.4 (NR) | NR | NS | |
| Genecept | |||||
| Clinical Global Impression–Improvement (≤ 3) | Perlis et al, 202061 | 87.7 (128/146) | 78.7 (118/150) | 1.11 (1.01–1.24) | .04 |
Abbreviations: CI, confidence interval; HAM-D6, 6-item Hamilton Depression Rating Scale; NR, not reported; NS, not significant; OR, odds ratio; PGI-I, Patient Global Impression of Improvement; PGx, pharmacogenomic-guided treatment; QIDS-C16, 16-item Quick Inventory of Depressive Symptomatology (clinician rated); RR, relative risk; TAU, treatment as usual.
Calculated from data provided in study. Estimates might vary from those in publication because of variation in statistical analyses used or rounding differences.
PGI-I ≤ 2 on at least two consecutive evaluations and maintained until final study visit.